Brokers Offer Predictions for Cassava Sciences, Inc.’s FY2025 Earnings (NASDAQ:SAVA)

Cassava Sciences, Inc. (NASDAQ:SAVAFree Report) – Equities research analysts at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for Cassava Sciences in a note issued to investors on Tuesday, October 8th. HC Wainwright analyst V. Bernardino anticipates that the company will post earnings per share of ($1.75) for the year. HC Wainwright has a “Buy” rating and a $116.00 price target on the stock. The consensus estimate for Cassava Sciences’ current full-year earnings is ($5.70) per share.

Separately, Rodman & Renshaw reiterated a “buy” rating and set a $107.00 price target on shares of Cassava Sciences in a report on Thursday, August 8th.

Read Our Latest Stock Analysis on SAVA

Cassava Sciences Stock Up 3.8 %

SAVA stock opened at $25.80 on Thursday. Cassava Sciences has a twelve month low of $8.79 and a twelve month high of $42.20. The stock’s 50 day moving average is $28.22 and its 200-day moving average is $22.17. The firm has a market capitalization of $1.24 billion, a PE ratio of -18.13 and a beta of -0.63.

Cassava Sciences (NASDAQ:SAVAGet Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.57. During the same period last year, the firm posted ($0.63) earnings per share.

Institutional Trading of Cassava Sciences

Several hedge funds have recently made changes to their positions in SAVA. Bluefin Capital Management LLC bought a new stake in shares of Cassava Sciences in the fourth quarter valued at $410,000. Cable Car Capital LLC bought a new stake in shares of Cassava Sciences in the fourth quarter valued at $1,204,000. Virtu Financial LLC raised its stake in shares of Cassava Sciences by 120.3% in the fourth quarter. Virtu Financial LLC now owns 49,128 shares of the company’s stock valued at $1,106,000 after buying an additional 26,824 shares during the period. NBC Securities Inc. raised its stake in shares of Cassava Sciences by 9.3% in the first quarter. NBC Securities Inc. now owns 7,650 shares of the company’s stock valued at $155,000 after buying an additional 650 shares during the period. Finally, Hennion & Walsh Asset Management Inc. raised its stake in shares of Cassava Sciences by 14.4% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 25,092 shares of the company’s stock valued at $509,000 after buying an additional 3,151 shares during the period. 38.05% of the stock is currently owned by institutional investors.

About Cassava Sciences

(Get Free Report)

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.

Featured Stories

Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.